ReviewOpen medicine (Warsaw, Poland)2026
Endometrial polyps recurrence: risk factors, prevention, and management.
Review in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hysteroscopic polypectomy with vs. without levonorgestrel-releasing intrauterine system in women with endometrial polyps and dysmenorrhea.Open medicine (Warsaw, Poland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endometrial polyps (EPs) are common intrauterine lesions often associated with abnormal uterine bleeding, infertility, and recurrence after treatment. Despite advances in diagnostic and surgical techniques, recurrence remains a clinical challenge. This review provides an overview of pathophysiology, risk factors, diagnostic strategies, and management options for recurrent EPs, emphasizing prevention. A literature search was conducted through PubMed, Scopus, Web of Science, Cochrane Library, and EMBASE, covering studies published up to November 30th, 2025. Content: Recurrent EPs are influenced by hormonal imbalances, genetic abnormalities, chronic inflammation, oxidative stress, and microbial dysbiosis. Risk factors include age, obesity, metabolic syndrome, incomplete resection, and altered microbiota. Diagnostic techniques include transvaginal ultrasound, hysteroscopy, and biomarker assays. Management options involve medical therapy (e.g., progesterone, LNG-IUS) and hysteroscopic removal. Preventive measures, such as post-polypectomy hormonal treatments, show promise in reducing recurrence. Summary and Outlook: A multidisciplinary approach combining precise surgery with targeted hormonal and microbiota therapies is essential for minimizing recurrence. Future research should focus on personalized management based on molecular and microbiological profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.